Plus   Neg

Experian H1 Profit Down, Organic Revenue Up; Declares Flat Dividend - Quick Facts

Experian plc. (EXPN.L), an information services company, on Tuesday reported that its first-half profit before tax declined 5 percent to $458 million from $480 million last year.

Basic earnings per share were 36.7 US cents, down 6 percent from 39 US cents a year ago.

Benchmark earnings per share were 47.9 cents, compared to 49.1 cents last year.

Revenue was $2.487 billion, slightly lower than last year's $2.495 billion. Revenues grew 3 percent at constant currency rates and 2 percent organically.

The second quarter revenues grew 5 percent organically, at the top end of guidance range, with growth stemmed largely from North America and Brazil which offset COVID-19 related declines in other territories.

Further, the company announced first interim dividend of 14.5 US cents per ordinary share, unchanged year-on-year.

Looking ahead for the third quarter, the company expects organic revenue growth in the range of 3 percent to 5 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT